Faculty of Medicine, Damascus University, Fayez Mansour Street, P. O. Box: 222, Damascus, Syrian Arab Republic.
Department of Oncology, Albairouni University Hospital, Faculty of Medicine, Damascus University, Harasta M5, Damascus, Syrian Arab Republic.
J Med Case Rep. 2024 Sep 4;18(1):405. doi: 10.1186/s13256-024-04734-6.
Breast cancer is the most common cancer in women. Progression-free survival for hormone receptor-positive/human epidermal growth factor receptor-2-negative metastatic breast cancer treated with endocrine therapy in combination with cyclin4/6-dependent kinase is approximately 25 months. This case represents metastatic breast cancer treated with endocrine therapy, leading to long-term survival.
A 40-year-old Syrian woman diagnosed with hormone receptor-negative breast cancer was treated surgically with adjuvant chemotherapy and radiotherapy. She developed local and nodal recurrences that were hormone receptor-positive, followed by a recurrence of malignant pleural effusion. She was initially treated with chemotherapy and then placed on endocrine therapy with a complete response from 2014 until now. The patient also suffered from adverse events of medications, such as heart failure and osteoporosis, which were treated appropriately.
This case demonstrates a long-lasting complete response to metastatic breast cancer with malignant pleural effusion. This shows the validity of endocrine therapy in recurrent hormone receptor-positive breast cancer, especially in countries that cannot afford targeted therapies or genetic tests. It also highlights the necessity for a better understanding of the prognostic and predictive factors.
乳腺癌是女性最常见的癌症。激素受体阳性/人表皮生长因子受体 2 阴性转移性乳腺癌患者接受内分泌治疗联合细胞周期蛋白 4/6 依赖性激酶治疗的无进展生存期约为 25 个月。本病例代表了接受内分泌治疗的转移性乳腺癌，导致长期生存。
一名 40 岁的叙利亚女性，被诊断为激素受体阴性乳腺癌，接受了辅助化疗和放疗的手术治疗。她出现了局部和淋巴结复发，这些复发是激素受体阳性的，随后出现了恶性胸腔积液的复发。她最初接受了化疗，然后接受了内分泌治疗，从 2014 年至今一直有完全缓解。该患者还出现了心力衰竭和骨质疏松等药物不良反应，这些不良反应得到了适当的治疗。
本病例显示了恶性胸腔积液转移性乳腺癌的持久完全缓解。这表明内分泌治疗在复发性激素受体阳性乳腺癌中的有效性，特别是在无法负担靶向治疗或基因检测的国家。这也强调了更好地理解预后和预测因素的必要性。
